Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island, United States of America.
Executive Office of Health and Human Services, State of Rhode Island, Cranston, Rhode Island, United States of America.
PLoS Med. 2019 Nov 19;16(11):e1002963. doi: 10.1371/journal.pmed.1002963. eCollection 2019 Nov.
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Between June 2018 and May 2019, we engaged a diverse stakeholder group (including directors of statewide health and social service agencies) to develop a statewide, patient-centered cascade of care for OUD for Rhode Island, a small state in New England, a region highly impacted by the opioid crisis. Through an iterative process, we modified the cascade of care defined by Williams et al. for use in Rhode Island using key national survey data and statewide health claims datasets to create a cross-sectional summary of 5 stages in the cascade. Approximately 47,000 Rhode Islanders (5.2%) were estimated to be at risk for OUD (stage 0) in 2016. At the same time, 26,000 Rhode Islanders had a medical claim related to an OUD diagnosis, accounting for 55% of the population at risk (stage 1); 27% of the stage 0 population, 12,700 people, showed evidence of initiation of medication for OUD (MOUD, stage 2), and 18%, or 8,300 people, had evidence of retention on MOUD (stage 3). Imputation from a national survey estimated that 4,200 Rhode Islanders were in recovery from OUD as of 2016, representing 9% of the total population at risk. Limitations included use of self-report data to arrive at estimates of the number of individuals at risk for OUD and using a national estimate to identify the number of individuals in recovery due to a lack of available state data sources.
Our findings indicate that cross-sectional summaries of the cascade of care for OUD can be used as a health policy tool to identify gaps in care, inform data-driven policy decisions, set benchmarks for quality, and improve health outcomes for persons with OUD. There exists a significant opportunity to increase engagement prior to the initiation of OUD treatment (i.e., identification of OUD symptoms via routine screening or acute presentation) and improve retention and remission from OUD symptoms through improved community-supported processes of recovery. To do this more precisely, states should work to systematically collect data to populate their own cascade of care as a health policy tool to enhance system-level interventions and maximize engagement in care.
鉴于美国(美国)阿片类药物过量危机的加速和迅速演变,需要新的策略来解决这一流行病,并有效地吸引和留住阿片类药物使用障碍(OUD)患者接受治疗。此外,需要用新方法利用健康数据来识别阿片类药物使用障碍患者护理连续体中的差距。
2018 年 6 月至 2019 年 5 月期间,我们与多元化的利益相关者群体(包括州卫生和社会服务机构主任)合作,为罗得岛制定了全州范围内以患者为中心的阿片类药物使用障碍护理连续体,罗得岛是新英格兰的一个小州,该地区深受阿片类药物危机的影响。通过迭代过程,我们使用关键的全国调查数据和全州健康索赔数据集修改了 Williams 等人定义的罗得岛阿片类药物使用障碍护理连续体,以创建 5 个连续体阶段的横断面总结。2016 年,估计约有 47000 名罗得岛人(5.2%)有阿片类药物使用障碍(OUD)的风险(第 0 阶段)。与此同时,26000 名罗得岛人有与 OUD 诊断相关的医疗索赔,占风险人群的 55%(第 1 阶段);第 0 阶段人群的 27%,即 12700 人,显示出开始使用 OUD 药物治疗(MOUD,第 2 阶段)的证据,18%,即 8300 人,显示出对 MOUD 的保留证据(第 3 阶段)。一项全国性调查的推断估计,截至 2016 年,罗得岛有 4200 人从 OUD 中康复,占总风险人群的 9%。限制包括使用自我报告数据来估计有 OUD 风险的人数,并使用全国估计数来确定由于缺乏可用的州数据源而康复的人数。
我们的研究结果表明,阿片类药物使用障碍护理连续体的横断面总结可作为卫生政策工具,用于确定护理差距,为数据驱动的政策决策提供信息,设定质量基准,并改善阿片类药物使用障碍患者的健康结果。通过改善社区支持的康复过程,有机会在开始阿片类药物治疗之前(即通过常规筛查或急性出现来识别阿片类药物使用障碍症状)增加参与度,并改善对阿片类药物使用障碍症状的保留和缓解。为此,各州应努力系统地收集数据,将其作为卫生政策工具纳入自己的连续体,以加强系统层面的干预措施并最大限度地提高对护理的参与度。